Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICARDIS HCT vs BYFAVO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.
Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.
Treatment of hypertension, alone or in combination with other antihypertensive agents
Improvement of excessive daytime sleepiness in adult patients with obstructive sleep apnea (OSA) as an adjunct to upper airway stimulation therapy
One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.
For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.
Telmisartan: terminal half-life ≈24 hours, allowing once-daily dosing. Hydrochlorothiazide: 6-15 hours (mean 10 hours).
Terminal elimination half-life is approximately 2-4 hours; clinical context: requires continuous infusion for sustained effect, as rapid clearance may lead to loss of efficacy.
Telmisartan is primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT1A8; it is not metabolized by CYP450 enzymes. Hydrochlorothiazide is not extensively metabolized; it is eliminated unchanged in the urine.
Primarily metabolized by CYP3A4 and CYP2D6, with minor contribution from CYP1A2.
Primarily biliary excretion (≈60%) and renal excretion (≈40%) as unchanged drug. Telmisartan: renal <1%, fecal >97%. Hydrochlorothiazide: renal >95% unchanged.
Renal excretion accounts for approximately 90% of the administered dose, with <5% as unchanged drug. Biliary/fecal elimination is minimal (<5%).
Telmisartan: >99.5% bound primarily to albumin and α1-acid glycoprotein. Hydrochlorothiazide: 40-68% bound to albumin.
Approximately 70-80% bound to human serum albumin and alpha-1-acid glycoprotein.
Telmisartan: 500 L (≈7 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: 0.8-1.2 L/kg, confined to extracellular fluid.
Volume of distribution (Vd) is 0.3-0.5 L/kg; clinical meaning: indicates moderate distribution into tissues, not extensive peripheral sequestration.
Telmisartan: absolute oral bioavailability ≈42-58% (dose-dependent). Hydrochlorothiazide: oral bioavailability ≈65-75%.
Bioavailability is not applicable for intravenous formulation; oral bioavailability is negligible due to extensive first-pass metabolism (<5% if administered orally).
Contraindicated if GFR <30 m L/min. No adjustment needed for GFR 30-89 m L/min. Monitor renal function.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), consider reduced infusion rate due to prolonged recovery times; specific dose not established.
Contraindicated in severe hepatic impairment (Child-Pugh C). Caution and possible dose reduction in mild-to-moderate impairment; maximum 40 mg/12.5 mg daily.
Child-Pugh A and B: No adjustment. Child-Pugh C: Reduce infusion rate by 50% and monitor for prolonged sedation; starting infusion at 0.75 mg/kg/hour is recommended.
Safety and efficacy not established in pediatric patients (<18 years).
Not approved for pediatric patients <18 years of age. Safety and efficacy not established.
No initial dose adjustment required; monitor blood pressure and renal function, especially with concurrent diuretic therapy.
For patients ≥65 years, consider lower initial infusion rate (1 mg/kg/hour) and reduce bolus doses; titrate carefully due to increased sensitivity and slower emergence from anesthesia.
None
Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).
Avoid use in pregnancy; can cause fetal harm when administered to a pregnant woman (discontinue as soon as possible when pregnancy is detected),May cause symptomatic hypotension in patients with volume or salt depletion,Monitor renal function; may cause acute renal failure, especially in patients with renal artery stenosis,Monitor serum electrolytes; risk of electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia) due to hydrochlorothiazide,May exacerbate or activate systemic lupus erythematosus,May cause acute angle-closure glaucoma (due to hydrochlorothiazide),May cause hypersensitivity reactions, including anaphylaxis and angioedema (telmisartan),Use with caution in patients with hepatic impairment (telmisartan),Use with caution in patients with diabetes or impaired renal function; may increase risk of renal impairment when used with NSAIDs or COX-2 inhibitors,Monitor for hyperuricemia and gout,May cause photosensitivity reactions
Risk of transient ischemic attacks and seizures; discontinue use if neurological symptoms occur.,May cause dose-related increases in blood pressure and heart rate; monitor cardiovascular status.,Not recommended in patients with unstable cardiovascular disease, recent myocardial infarction, or stroke.,Potential for drug interactions with strong CYP3A4 inhibitors or inducers.,May cause insomnia, anxiety, or restlessness.
Hypersensitivity to telmisartan, hydrochlorothiazide, or any component of the formulation,Anuria (due to hydrochlorothiazide),Concomitant use with aliskiren in patients with diabetes mellitus,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment
Hypersensitivity to BYFAVO or any of its components,Severe hepatic impairment (Child-Pugh Class C)
Avoid high-potassium foods (bananas, oranges, tomatoes, spinach, salt substitutes) due to telmisartan's potassium-sparing effect. Hydrochlorothiazide may cause hypomagnesemia and hypokalemia; ensure adequate intake of magnesium-rich foods (nuts, whole grains) and potassium-rich foods (if not contraindicated). Avoid excessive alcohol intake which can increase hypotensive effect.
No specific food interactions are reported. However, because sedation may cause nausea, avoid heavy meals immediately before sedation. Grapefruit juice does not significantly interact with remimazolam.
First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligohydramnios, skull ossification defects, hypotension, and anuria. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Effective contraception required.
Telmisartan is excreted in human milk in very low concentrations; M/P ratio unknown for telmisartan. Hydrochlorothiazide is excreted in breast milk; M/P ratio approximately 1.6. Avoid breastfeeding due to potential for adverse effects on the infant, including electrolyte disturbances and hypotension.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No dose adjustment data specific to pregnancy for Micardis HCT. Due to risk of fetal harm, use is contraindicated in pregnancy; discontinue as soon as pregnancy is detected. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may theoretically require dose adjustment, but no established guidelines.
No pharmacokinetic data in pregnancy; standard dosing is not recommended as drug is contraindicated. If use is unavoidable, no specific dose adjustment guidelines exist; use with extreme caution and consider alternative therapy.
MICARDIS HCT (telmisartan/hydrochlorothiazide) is a fixed-dose combination for hypertension not controlled on monotherapy. Monitor renal function, electrolytes (especially potassium and sodium), and volume status. Avoid in severe renal impairment (Cr Cl <30 m L/min) and anuria. Assess for hypotension, particularly in volume-depleted patients. Use with caution in hepatic impairment, diabetes, and history of angioedema. May cause fetal harm in pregnancy; discontinue as soon as possible. Telmisartan is not dialyzable.
BYFAVO (remimazolam) is an ultra-short-acting benzodiazepine for procedural sedation. Onset within 1-2 minutes, recovery typically within 10 minutes. Flumazenil is the reversal agent. Monitor for respiratory depression; have resuscitation equipment available. Avoid in severe hepatic impairment. Coadministration with opioids increases sedation depth; reduce doses accordingly.
Take exactly as prescribed; do not skip doses or take double doses.,Notify your doctor immediately if you become pregnant or plan to become pregnant.,Avoid alcohol, NSAIDs, and salt substitutes containing potassium.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, confusion, or decreased urination.,This medication may increase blood sugar; monitor if you have diabetes.
You will be closely monitored during the procedure. Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,Inform your healthcare provider if you have a history of liver disease, glaucoma, or substance abuse.,Do not consume alcohol for at least 24 hours after sedation.,You may experience temporary memory loss or drowsiness; arrange for a responsible adult to accompany you home.,Report any unusual side effects such as prolonged drowsiness, difficulty breathing, or allergic reactions (rash, swelling) to your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICARDIS HCT vs BYFAVO, answered by our medical review team.
MICARDIS HCT is a Antihypertensive Combination (ARB + Thiazide Diuretic) that works by Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.. BYFAVO is a Benzodiazepine that works by Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICARDIS HCT and BYFAVO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICARDIS HCT is: One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.. The standard adult dose of BYFAVO is: For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICARDIS HCT and BYFAVO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICARDIS HCT is classified as Category C. First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligoh. BYFAVO is classified as Category C. BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.